IRIS
PICHINI, SIMONA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.731
AS - Asia 2.287
EU - Europa 2.233
SA - Sud America 379
Continente sconosciuto - Info sul continente non disponibili 180
AF - Africa 158
OC - Oceania 13
Totale 12.981
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.497
SG - Singapore 871
IT - Italia 645
RU - Federazione Russa 398
CN - Cina 381
VN - Vietnam 375
BR - Brasile 292
HK - Hong Kong 270
FR - Francia 198
DE - Germania 161
IE - Irlanda 156
GB - Regno Unito 149
SE - Svezia 136
UA - Ucraina 112
CA - Canada 108
IN - India 92
BD - Bangladesh 75
CI - Costa d'Avorio 69
NL - Olanda 56
MX - Messico 50
FI - Finlandia 48
JP - Giappone 37
PL - Polonia 36
ZA - Sudafrica 30
BE - Belgio 28
TR - Turchia 28
IQ - Iraq 27
AR - Argentina 24
ES - Italia 21
AT - Austria 20
EC - Ecuador 17
LT - Lituania 17
ID - Indonesia 15
MA - Marocco 15
PK - Pakistan 15
CO - Colombia 14
HN - Honduras 13
IL - Israele 13
PH - Filippine 13
SV - El Salvador 11
VE - Venezuela 11
TH - Thailandia 10
AU - Australia 9
CL - Cile 9
KR - Corea 9
PR - Porto Rico 9
AE - Emirati Arabi Uniti 8
CR - Costa Rica 8
EG - Egitto 8
GT - Guatemala 7
JM - Giamaica 7
TN - Tunisia 7
TT - Trinidad e Tobago 7
BG - Bulgaria 6
DK - Danimarca 6
DZ - Algeria 6
IR - Iran 6
SA - Arabia Saudita 6
UZ - Uzbekistan 6
GP - Guadalupe 5
KE - Kenya 5
MY - Malesia 5
NP - Nepal 5
CW - ???statistics.table.value.countryCode.CW??? 4
ET - Etiopia 4
MD - Moldavia 4
NZ - Nuova Zelanda 4
PT - Portogallo 4
RO - Romania 4
RS - Serbia 4
SC - Seychelles 4
UY - Uruguay 4
AZ - Azerbaigian 3
BY - Bielorussia 3
CH - Svizzera 3
CZ - Repubblica Ceca 3
MT - Malta 3
NI - Nicaragua 3
OM - Oman 3
PA - Panama 3
PE - Perù 3
TW - Taiwan 3
BO - Bolivia 2
GR - Grecia 2
HR - Croazia 2
HU - Ungheria 2
JO - Giordania 2
MO - Macao, regione amministrativa speciale della Cina 2
PS - Palestinian Territory 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
AL - Albania 1
BB - Barbados 1
BN - Brunei Darussalam 1
BS - Bahamas 1
CD - Congo 1
CM - Camerun 1
DM - Dominica 1
EE - Estonia 1
EU - Europa 1
Totale 12.791
Salva come PNG Salva come JPEG
Città #
Ashburn 1.234
Dallas 604
Singapore 571
San Jose 331
Chandler 328
Hong Kong 265
Des Moines 241
Council Bluffs 238
Fairfield 227
New York 201
Los Angeles 193
Jacksonville 177
Dublin 155
Beijing 135
Seattle 127
Houston 114
Boardman 112
Ho Chi Minh City 109
Wilmington 106
Hanoi 99
Woodbridge 98
Rome 86
Cambridge 83
Lauterbourg 78
The Dalles 76
San Francisco 75
Moscow 70
Santa Clara 70
Abidjan 69
Orem 67
Phoenix 66
Denver 63
Lawrence 58
Milan 58
Princeton 58
Munich 54
Atlanta 53
San Mateo 48
London 47
Chicago 45
São Paulo 45
Ann Arbor 43
Montreal 43
Buffalo 38
Brooklyn 36
Turin 36
Ancona 32
Helsinki 32
Warsaw 31
Mexico City 29
Tokyo 28
San Diego 25
Boston 24
Hefei 24
Toronto 23
Da Nang 21
Pune 21
Frankfurt am Main 20
Haiphong 20
Brussels 18
Washington 18
Chennai 17
Baghdad 16
Memphis 16
Turku 15
Johannesburg 14
Manchester 14
Shanghai 14
Stockholm 14
Amsterdam 13
Miano 13
Vilnius 12
Centro 11
Milwaukee 11
North Bergen 11
San Salvador 11
Vienna 11
Boydton 10
Columbus 10
Falls Church 10
Honolulu 10
Pittsburgh 10
Poplar 10
Canary Wharf 9
Kilburn 9
Mohali 9
Newark 9
Salt Lake City 9
Verona 9
Cape Town 8
Florence 8
Guarulhos 8
Norwalk 8
Querétaro 8
Quito 8
Rio de Janeiro 8
Calgary 7
Charlotte 7
Guangzhou 7
Izmir 7
Totale 7.907
Salva come PNG Salva come JPEG
Nome #
UHPLC-MS-MS Determination of THC, CBD and Their Metabolites in Whole Blood of Light Cannabis Smokers 1.012
Δ9-Tetrahydrocannabinol and Cannabidiol Time Courses in the Sera of "Light Cannabis" Smokers: Discriminating Light Cannabis Use from Illegal and Medical Cannabis Use 623
THC and CBD concentrations in blood, oral fluid and urine following a single and repeated administration of "light cannabis" 316
A comprehensive HPLC–MS-MS screening method for 77 new psychoactive substances, 24 classic drugs and 18 related metabolites in blood, urine and oral fluid 296
Disposition of cannabinoids and their metabolites in serum, oral fluid, sweat patch and urine from healthy individuals treated with pharmaceutical preparations of medical cannabis 292
Maternal hair testing to disclose self-misreporting in drinking and smoking behavior during pregnancy 257
Human diagnostic markers for intake of semi-synthetic cannabinoids (9R)- and (9S)-hexahydrocannabinol 251
Disposition of phytocannabinoids, their acidic precursors and their metabolites in biological matrices of healthy individuals treated with vaporized medical cannabis 243
Human metabolism and pharmacological profiling of protonitazepyne and metonitazepyne, two highly potent nitazenes: prediction of main metabolite activity based on µ-opioid receptor docking simulations 238
Acute Pharmacological Effects and Oral Fluid Concentrations of the Synthetic Cannabinoids JWH-122 and JWH-210 in Humans After Self-Administration: An Observational Study 234
New challenges in clinical and forensic toxicology 192
Analysis of perfluoroalkyl substances (PFAS) in conventional and unconventional matrices: Clinical outcomes 189
“Tranq-dope”: The first fatal intoxication due to xylazine-adulterated heroin in Italy 184
Acute Intoxications and Fatalities Associated with Benzimidazole Opioid (Nitazene Analog) Use: A Systematic Review 183
UHPLC-MS/MS analysis of cannabidiol metabolites in serum and urine samples. Application to an individual treated with medical cannabis 178
Disposition of Hexahydrocannabinol Epimers and Their Metabolites in Biological Matrices following a Single Administration of Smoked Hexahydrocannabinol: A Preliminary Study 177
Usefulness of Oral Fluid for Measurement of Methylone and Its Metabolites: Correlation with Plasma Drug Concentrations and the Effect of Oral Fluid pH 170
Dipyanone, a new methadone-like synthetic opioid: In vitro and in vivo human metabolism and pharmacological profiling 170
Evaluation of long-term stability of cannabinoids in standardized preparations of cannabis flowering tops and cannabis oil by ultra-high-performance liquid chromatography tandem mass spectrometry 166
Disposition of cannabidiol metabolites in serum and urine from healthy individuals treated with pharmaceutical preparations of medical cannabis 165
Analytical procedures and blood threshold values to ascertain driving in a stae of psycho-physical impairment from drugs abuse|Procedure analitiche e valori decisionali ematici per accertare la guida in stato di alterazione psicofisica da sostanze d'abuso 164
Stability and Degradation Pathways of Different Psychoactive Drugs in Neat and in Buffered Oral Fluid 160
Monitoring Prenatal Exposure to Buprenorphine and Methadone 157
Toxicology and analysis of psychoactive tryptamines 154
Herbal preparations of medical cannabis: A vademecum for prescribing doctors 148
Methylone and MDMA Pharmacokinetics Following Controlled Administration in Humans 145
QuEChERS Extraction and Simultaneous Quantification in GC-MS/MS of Hexahydrocannabinol Epimers and Their Metabolites in Whole Blood, Urine, and Oral Fluid 144
Acute Intoxications and Fatalities From Illicit Fentanyl and Analogues: An Update 141
Pharmacological effects of methylone and MDMA in humans 141
Testing Unconventional Matrices to Monitor for Prenatal Exposure to Heroin, Cocaine, Amphetamines, Synthetic Cathinones, and Synthetic Opioids 140
Analytical Strategies to Disclose Repeated Consumption of New Psychoactive Substances by Hair Analysis 139
Ultra-high-performance liquid chromatography-tandem mass spectrometry assay for quantifying fentanyl and 22 analogs and metabolites in whole blood, urine, and hair 134
Determination of the synthetic cannabinoids JWH-122, JWH-210, UR-144 in oral fluid of consumers by GC-MS and quantification of parent compounds and metabolites by UHPLC-MS/MS 134
Commentary - Heroin purity and adulteration: An updated snapshot from the Italian Early Warning System 134
Recent challenges and trends in forensic analysis: Δ9-THC isomers pharmacology, toxicology and analysis 133
European drug users at risk from illicit fentanyls mix 133
UHPLC-MS/MS analysis of cannabidiol and its metabolites in serum of patients with resistant epilepsy treated with CBD formulations 131
A fatal chemsex case involving γ-butyrolactone and 4-methylethcathinone 129
Correspondence 128
Cannabinoids determination in bronchoalveolar lavages of cannabis smokers with lung disease 127
Dilute and shoot ultra-high performance liquid chromatography tandem mass spectrometry (UHPLC–MS/MS) analysis of psychoactive drugs in oral fluid 125
Cannabidiol adverse effects and toxicity 125
Pharmacology and legal status of cannabidiol 124
Liquid Chromatography High-Resolution Mass Spectrometry in Forensic Toxicology: What are the Specifics of Method Development, Validation and Quality Assurance for Comprehensive Screening Approaches? 123
Evaluation of Short-Term Stability of Different Nitazenes Psychoactive Opioids in Dried Blood Spots by Liquid Chromatography-High-Resolution Mass Spectrometry 123
Monitoring Perinatal Exposure to Cannabis and Synthetic Cannabinoids 123
The National Early Warning System, a web-based platform to prevent the spread of New Psychoactive Substances 123
Analytical advances in clinical and forensic toxicology. Second part 122
Comment on "direct Monitoring of Exogenous γ-Hydroxybutyric Acid in Body Fluids by NMR Spectroscopy": Several Issues to Consider When Quantifying γ-Hydroxybutyric Acid in Biological Matrixes 118
Sweat Testing for the Detection of Methylone after Controlled Administrations in Humans 117
Measurement uncertainty in forensic toxicology 116
Effects of subtoxic 3-methylmethcathinone concentrations on neuronal cell electrical properties 115
Development of enantioselective high-performance liquid chromatography-tandem mass spectrometry method for quantitative determination of methylone and some of its metabolites in oral fluid 115
A “special dose” of ethics in forensic toxicology 113
Ultra-high-performance liquid chromatography tandem mass spectrometry assay for determination of endogenous ghb and ghb-glucuronide in nails 112
Determination of cannabinoids in oral fluid and urine of "light cannabis" consumers: A pilot study 109
Advances and future developments in forensic toxicology: From standard practices to new psychoactive substances 108
Synthetic cathinones related fatalities: an update 108
Pharmacotoxicology of non-fentanyl derived new synthetic opioids 107
Herbal highs: Review on Psychoactive Effects and Neuropharmacology 106
Clarifying methodological issues in cannabinoids determination in bronchoalveolar lavages 105
Cannabis: Neurological correlates in abuse and medical use 103
Correlation between Blood and Oral Fluid Psychoactive Drug Concentrations and Cognitive Impairment in Driving under the Influence of Drugs 102
Screening methods for rapid determination of new psychoactive substances (NPS) in conventional and non-conventional biological matrices 102
The complex and constantly evolving public health threat of new psychoactive substances in Italy: Addressing the main functions of a national observatory of drugs 102
Medicinal cannabis and synthetic cannabinoid use 100
Comprehensive Monitoring of Psychoactive Substances in Psychiatric Patients Using Liquid Chromatography-High-Resolution Mass Spectrometry: A Key Tool for Treatment Planning and Understanding Consumption Patterns in Rome, Italy 99
Segmental hair testing of triazolam to unmask a suspected case of idiopathic recurrent Stupor 95
Stability of cannabinoids in cannabis FM1 flowering tops and oil preparation evaluated by ultra-high performance liquid chromatography tandem mass spectrometry 92
Metabolic pathways and potencies of new fentanyl analogs 92
Erratum to Reduced prevalence of fetal exposure to alcohol in Italy: a nationwide survey American Journal of Obstetrics & Gynecology MFM. Volume 5, Issue 6, June 2023, 100944 89
Global prevalence of fetal alcohol spectrum disorder in Italy 88
The issue of psychotropic drug monitoring in sexual assault victims 87
Molecular Insights of New Psychoactive Substances (NPS) 2.0 83
The importance of biomarkers of fetal exposure to alcohol and psychotropic drugs in early diagnosis: A case report 82
Editorial: Drug-drug interactions in pharmacology 80
Molecular Insights on New Psychoactive Substances (NPSs) 80
GHB concentration in breast milk of narcoleptic women treated with sodium oxybate. How important it is to be careful when interpreting values 79
The new synthetic benzimidazole opioid etonitazepipne: an emerging fatal harm and a challenge for laboratory medicine 78
GHB side effects: The need to clearly document drug dose and administration history 76
Nails in Forensic Toxicology: an Update 76
Target Analysis of NPS in Oral Fluid 74
Editorial: The challenge posed by new synthetic opioids: Pharmacology and toxicology 72
Editorial: Analytical Advances in Clinical and Forensic Toxicology 70
New psychoactive substances: A matter of time 70
The value of toxicological and forensic analyses in the global challenge to health risks caused by new psychoactive substances 62
GHB-facilitated sexual assaults: How to proper assess a single GHB exposure in hair 59
Totale 12.981
Salva come PNG Salva come JPEG
Categoria #
all - tutte 52.426
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 52.426
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022321 0 0 0 7 3 41 4 29 46 34 55 102
2022/20231.093 88 124 79 75 45 308 8 59 211 3 75 18
2023/2024590 79 12 80 53 83 115 26 20 8 17 14 83
2024/20251.693 117 118 88 71 86 124 141 92 347 115 154 240
2025/20264.878 351 480 336 343 537 256 820 394 361 417 182 401
2026/20273.201 1.004 820 746 631 0 0 0 0 0 0 0 0
Totale 12.981